ライフサイエンスコーパス: thiazide diuretic

1 than treatment with an ACE inhibitor plus a thiazide diuretic.

2 cker, an angiotensin receptor blocker, and a thiazide diuretic.

3 nts receiving dialysis and 847 discharged on thiazide diuretics.

4 al features of GS with a blunted response to thiazide diuretics.

5 ive classes of antihypertensive medications, thiazide diuretics.

6 f action of SPIRO and a potential target for thiazide diuretics.

7 ressure 137/75 mm Hg [17/9]) who were not on thiazide diuretics.

8 1.43 to 3.91) compared with those prescribed thiazide diuretics.

9 d correction of physiologic abnormalities by thiazide diuretics.

10 ihypertensive drug than in those receiving a thiazide diuretic (-2.38 mm Hg [-6.16 to 1.40]).

11 Thiazide diuretics, ACE-inhibitors or angiotensin recept

12 The potency series of thiazide diuretic action (acetazolamide > chlorothiazide

13 onstrating the efficacy of very low doses of thiazide diuretics added to other antihypertensive agent

14 open-label antihypertensive therapy (mostly thiazide diuretics) added as needed to control blood pre

15 Thiazide diuretic agents are widely used for prevention

16 pyridine CCBs (hazard ratio 1.49 considering thiazide diuretic agents as a comparator; 95% CI, 1.04-2

17 should be given to medical treatment with a thiazide diuretic and/or citrate therapy.

18 Previous research has suggested that thiazide diuretics and beta-blockers may promote the dev

19 rvational studies on the association between thiazide diuretics and colorectal cancer risk is conflic

20 The studies most strongly support the use of thiazide diuretics and long-acting calcium channel block

21 , genetic disorders, and medications such as thiazide diuretics and supplements such as calcium, vita

22 beta-blockers, calcium-channel blockers, or thiazide diuretics and the likelihood of a positive or n

23 n mechanisms and sites of action of loop and thiazide diuretics and the similarity of their chronic e

24 ARB), calcium channel blocker, beta-blocker, thiazide diuretic, and other antihypertensive medication

25 46.6%) calcium channel blockers, 180 (16.7%) thiazide diuretics, and 277 (25.7%) other antihypertensi

26 ce of PHAII phenotypes, their sensitivity to thiazide diuretics, and the observation that they consti

27 Thiazide diuretics, angiotensin II receptor blockers, an

28 However, it is reasonable to conclude that thiazide diuretics, angiotensin-II receptor blockers, an

29 Thiazide diuretics are among the most commonly prescribe

30 As thiazide diuretics are among the most efficacious agents

31 Thiazide diuretics are among the most widely used treatm

32 We aimed to determine whether thiazide diuretics are associated with an increased colo

33 Thiazide diuretics are associated with glucose intoleran

34 Thiazide diuretics are commonly prescribed for the treat

35 essential hypertension remains unknown, but thiazide diuretics are frequently recommended as first-l

36 Thiazide diuretics are frequently used in these patients

37 the major conclusion of this trial was that thiazide diuretics are superior in preventing 1 or more

38 The initial ALLHAT conclusion, that thiazide diuretics are superior to angiotensin-convertin

39 Thiazide diuretics are used to treat hypertension; howev

40 Thiazide diuretics are used worldwide as a first-choice

41 In this large pragmatic trial of thiazide diuretics at doses commonly used in clinical pr

42 nts with normal plasma K+ and aldosterone, a thiazide diuretic, bendroflumethiazide, would be as effe

43 Overall, the use of thiazide diuretics, beta-blockers, angiotensin-convertin

44 scriptomics) to identify novel biomarkers of thiazide diuretics BP response.

45 suggests VASP as a potential determinant of thiazide diuretics BP response.

46 otensin II receptor blockers, beta-blockers, thiazide diuretics, calcium channel blockers, and metfor

47 ts were used to test the hypothesis that the thiazide diuretic chlorthalidone would decrease urine ca

48 recommends pharmacologic monotherapy with a thiazide diuretic, citrate, or allopurinol to prevent re

49 How specific thiazide diuretics compare in regard to safety and clini

50 on and potentially severe adverse event, and thiazide diuretics constitute a leading cause of drug-in

51 Thiazide diuretic drugs act in the distal convoluted tub

52 However, although thiazide diuretic drugs have been advocated as first-lin

53 eabsorption mechanisms provides insight into thiazide diuretic efficacy.

54 e in the CLOROTIC trial (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure).

55 ta have called into question the efficacy of thiazide diuretics for the prevention of kidney stones.

56 It is unclear whether different thiazide diuretics have a differential impact on kidney

57 Thiazide diuretics have proven themselves effective agai

58 We found that men using NSAIDs, statins, and thiazide diuretics have reduced PSA levels by clinically

59 ciuric stones, sodium restriction along with thiazide diuretics helps to reduce urinary calcium.

60 ny diuretic (HR 1.48 [95% CI 1.11, 1.98]), a thiazide diuretic (HR 1.44 [95% CI 1.00, 2.10]), or a lo

61 ature evaluating the combination of loop and thiazide diuretics in patients with heart failure in ord

62 The intact hypocalciuric response to a thiazide diuretic indicates that inactivation of the ClC

63 The cohort included 377,760 thiazide diuretic initiators and 364,300 dCCB initiators

64 Between 1990-2018, we compared thiazide diuretic initiators with dCCB initiators and es

65 trol, and drug therapy emphasized the use of thiazide diuretic intensification and addition of spiron

66 Potassium depletion by thiazide diuretics is associated with a rise in blood gl

67 i-drug combination, particularly including a thiazide diuretic, is very often necessary and should be

68 suggest that inexpensive and well-tolerated thiazide diuretics may be especially effective in preven

69 directly in cells expressing NCC, indicating thiazide diuretics may be particularly effective for low

70 apy with beta-receptor blockers, digoxin and thiazide diuretics may worsen sexual dysfunction owing t

71 Thiazide diuretics, niacin, and beta-adrenergic blockers

72 ), B blockers, calcium channel blockers, and thiazide diuretics on cancer risk in one-stage individua

73 , continuous infusions, or the addition of a thiazide diuretic or aldosterone antagonist.

74 er exclusion of participants who were taking thiazide diuretics or those with diabetes.

75 red with not using any diuretic, not using a thiazide diuretic, or not using a loop diuretic, respect

76 drug (NSAID; P = .03), statin (P = .01), and thiazide diuretic (P = .025) intake was inversely relate

77 patients with truly resistant hypertension, thiazide diuretics, particularly chlorthalidone, should

78 blockers, putting them on equal footing with thiazide diuretics, renin-angiotensin system blockers (e

79 nd unravel a complex mechanism that explains thiazide diuretic resistance.

80 use of B blockers (RR 1.48 [1.27-1.72]) and thiazide diuretics (RR 1.20 [1.07-1.35]) increased this

81 The combination of statins and thiazide diuretics showed the greatest reduction in PSA

82 They also illuminate how thiazide diuretics specifically interact with the NCC an

83 ent with alternate mechanism of actions (eg, thiazide diuretics, such as metolazone), or need for ult

84 Thiazide diuretics (TD) are commonly prescribed anti-hyp

85 safety and clinical outcomes associated with thiazide diuretics, these results suggest that there is

86 Thiazide diuretics (thiazides) are among the most widely

87 reasing diuretic dosage, concurrent use of a thiazide diuretic to inhibit downstream NaCl reabsorptio

88 nitiated HF medications ranged from 0.57 for thiazide diuretics to 0.77 for sodium-glucose cotranspor

89 d not discourage physicians from prescribing thiazide diuretics to nondiabetic adults who have hypert

90 nce has been available to support the use of thiazide diuretics to treat hypertension in patients wit

91 Thiazide diuretics treat the disease, fostering the view

92 pediatric patients indicate that citrate or thiazide diuretic treatment may improve BMD.

93 Five years of NSAID, statin, and thiazide diuretic use was associated with PSA levels low

94 with blood pressure less than 140/90 mm Hg; thiazide diuretics used in multidrug hypertensive regime

95 CC alone and in complex with a commonly used thiazide diuretic using cryo-electron microscopy.

96 -analysis of all cohorts, genetic proxies of thiazide diuretics were associated with a lower odds of

97 Genetic proxies of thiazide diuretics were associated with higher serum cal

98 enetic association study, genetic proxies of thiazide diuretics were associated with reduced kidney s

99 Genetic proxies of thiazide diuretics were derived from the International C

100 Genetic proxies of thiazide diuretics were genetic variants in the thiazide

101 Compared with dCCBs, thiazide diuretics were not associated with an overall i

102 Compared with dCCBs, thiazide diuretics were not associated with colorectal c

103 , subjects with hypertension who were taking thiazide diuretics were not at greater risk for the subs

104 Loop or thiazide diuretics were used in all 14 patients, and ang

105 l nephron of the kidney and is the target of thiazide diuretics, which are commonly prescribed to tre

106 egulates blood pressure and is the target of thiazide diuretics, which have been widely prescribed as

107 Disease features are reversed by thiazide diuretics, which inhibit the Na-Cl cotransporte

108 ients except for NSAIDs, ACE inhibitors, and thiazide diuretics, which were more prevalent in black p

109 ceptor blocker, calcium channel blocker, and thiazide diuretic) with estimated glomerular filtration

110 serotonin reuptake inhibitors, statins, and thiazide diuretics), with evaluation of how often drugs